Fish Oil Doesn’t Protect Aging Brains? Not Even High-Dose DHA Supplements Improved Memory In 2-Year Trial

For years, fish oil supplements have been marketed as brain boosters, lining pharmacy shelves with promises of sharper thinking and a lower risk of Alzheimer’s disease. Many older adults take them every day. Now, a rigorous clinical trial has delivered a sobering finding: even at high doses, even when the omega-3 fatty acid DHA was confirmed to reach the brain’s surrounding fluid, it made no measurable difference in memory, thinking ability, or brain structure over two years in this trial.

Published in the journal eBioMedicine, the study enrolled cognitively healthy older adults who ate little DHA-rich food and carried at least one dementia risk factor, an important high-risk group for Alzheimer’s prevention. Researchers paid particular attention to those carrying a gene variant called APOE ε4, the strongest known genetic risk factor for the disease, who made up nearly half the participants. Carriers appear to process and use DHA differently than non-carriers, and enrolling people who were already getting very little DHA from their diet let the team test whether higher doses might protect the brains thought most likely to benefit, before any symptoms of dementia appear.

One feature set this trial apart from earlier fish oil research: what the scientists could measure directly. Rather than simply giving people capsules and testing their memory months later, the team collected fluid from around the spine, the same fluid that surrounds the brain, and confirmed that DHA was reaching the brain’s central nervous system environment, demonstrating what researchers call “CNS target engagement.” That kind of direct confirmation had been missing from many earlier trials. And yet, even with proof that DHA was reaching the brain’s surrounding fluid, participants showed no cognitive or brain-structure advantages over those taking a placebo.

A Fish Oil Trial Built to Settle an Old Question

Earlier fish oil trials shared one weak spot: no one could be sure the supplement was reaching the brain in meaningful amounts. Most past studies used doses of one gram per day or less and found no cognitive benefit, but critics argued the doses might simply have been too low to matter. This new trial was designed specifically to answer that question.

Researchers at the University of Southern California enrolled 365 adults between the ages of 55 and 80. All of them had normal thinking and memory, reported eating very little fish or DHA-rich food, less than 200 milligrams per day, and had at least one risk factor for dementia, such as high blood pressure, obesity, or physical inactivity. About 39% of participants were Hispanic, and 58% were women, making the study more diverse than many Alzheimer’s prevention trials.

Participants were randomly assigned to take either 2,000 milligrams of DHA per day, many times the amount they were getting from food, or identical-looking placebo capsules filled with corn and soybean oil. Across 24 months, neither the participants nor the researchers knew who was getting which treatment, with brain scans and cognitive testing done at the start and the end.

Spinal Fluid Confirmed the DHA Reached the Brain’s Fluid

One technically demanding part of the study involved a subset of 167 participants who agreed to have spinal fluid collected, a procedure that offers a direct window into the brain’s chemical environment. At six months, participants taking DHA showed a sharp rise in the ratio of DHA to another fatty acid in their spinal fluid, while the placebo group showed almost no change. In the DHA group, that rise was large and statistically clear.

Reaching the brain was the trial’s primary goal: to show that high-dose DHA can get into the brain’s central nervous system environment in people who have been running low on the nutrient. On that front, the experiment was a clear success. Red blood cell measurements told a similar story, with a standard gauge of the body’s omega-3 status more than doubling in the DHA group over 24 months while staying flat in the placebo group.

DHA was reaching the brain’s surrounding fluid. Whether that biochemical change would translate into something a person could feel, or a brain scan could detect, was the open question.

No Benefit for Memory or Brain Structure

It did not. After 24 months, scores on a broad battery of cognitive tests improved slightly in both groups, but by nearly identical amounts. Participants taking DHA improved by an average of 2.76 points on the cognitive scale; those taking placebo improved by 2.67 points. That gap is so small as to be meaningless. No specific thinking skill tested showed a benefit, including memory, attention, language, or spatial reasoning. APOE ε4 carriers and non-carriers responded the same way.

Brain scans told a similar story. Both groups had a small, gradual shrinkage in the hippocampus, the brain region most tied to memory and one of the first areas damaged in Alzheimer’s disease, but the rate of shrinkage was the same in both groups. Measurements of the thickness of the brain’s outer layer also showed no treatment effect.

Complications did affect the trial. A 38% dropout rate, driven mainly by the COVID-19 pandemic, reduced the study’s ability to detect smaller effects. Participants who dropped out were more likely to be Hispanic, have lower education levels, and have lower baseline DHA levels, which the researchers acknowledged could affect how broadly the results apply.

Where Fish Oil Research Goes From Here

Authors of the study are direct about what the findings indicate. Getting more DHA into the brain’s environment is clearly achievable with high-dose supplements, but brain enrichment alone does not appear to be enough to protect thinking and memory in otherwise healthy older adults over a two-year period. They suggest that enzymes in the brain may actively break down DHA after it arrives, possibly undoing any benefit before it can build up, though they note this remains a hypothesis rather than a measured result. In people with the APOE ε4 gene, the brain’s system for transporting, incorporating, and breaking down DHA may be altered in ways that simply adding more of the raw material cannot fix.

A broader pattern across the research literature points the same way. Reviews of clinical trials examining omega-3 supplementation in people without dementia have found that cognitive benefits are the exception rather than the rule, and large studies of healthy older adults over several years have also come up empty. Across those studies, the authors argue, the evidence now points away from giving everyone more fish oil and toward understanding how specific individuals process DHA, with the goal of designing personalized treatments that address several risk factors at once rather than relying on one supplement.

On safety, the results were reassuring. Adverse events were reported at nearly identical rates in both groups, and the paper reports no serious adverse events were attributed to the treatment. Two deaths occurred during the trial, one in each group, and neither was connected to the study drug.

This trial answers a question that has persisted for some time in fish oil research. Among these older adults at risk for dementia, high-dose DHA reached the brain’s surrounding fluid over two years, and it still did not improve cognition or brain structure. This points future research toward a harder question, why some brains struggle to use DHA effectively, and toward more personalized approaches that go beyond single-nutrient supplements.

---

Disclaimer: This article describes a randomized, double-blind, placebo-controlled trial, a strong design for testing cause and effect. Its null result means high-dose DHA showed no cognitive or brain-structure benefit over two years in this specific population: cognitively healthy older adults with low omega-3 intake and at least one dementia risk factor. That does not prove fish oil is useless for everyone, and the 38% dropout (driven largely by COVID-19) along with the relatively young, highly educated, single-center sample limits how far the findings extend. Nothing here is medical advice; talk to a clinician before starting or stopping any supplement.

---